Currently, a combination of tumor sequencing and p-MHC prediction allows the identification of candidate tumor neoantigen peptides in tumor patients, leading to the synthesis of personalized peptides for tumor-targeted therapy (22–26). This evidence concerns the gene HLA-C and neoplasm.